Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Group A streptococcal vaccines: facts versus fantasy

Steer, A., Batzloff, M., Mulholland, E. Kim and Carapetis, Jonathan R. (2009). Group A streptococcal vaccines: facts versus fantasy. Current Opinion in Infectious Diseases,22(6):544-552.

Document type: Journal Article

IRMA ID 10666xPUB27
Title Group A streptococcal vaccines: facts versus fantasy
Author Steer, A.
Batzloff, M.
Mulholland, E. Kim
Carapetis, Jonathan R.
Journal Name Current Opinion in Infectious Diseases
Publication Date 2009
Volume Number 22
Issue Number 6
ISSN 0951-7375   (check CDU catalogue  open catalogue search in new window)
Start Page 544
End Page 552
Total Pages 9
Place of Publication United States
Publisher Lippincott Williams & Wilkins, Ltd.
HERDC Category C1 - Journal Article (DEST)
Abstract Purpose of review: This review provides an overview of progress of the development of group A streptococcal (GAS) vaccines with a focus on recent advances.

Recent findings: Historically, GAS vaccine development has focused on the N-terminus of the M protein, which ultimately led to successful phase I/II clinical trials of a 26-valent recombinant M protein vaccine in 2004-2005. More recently, interest in antigens conserved among most, if not all, group A streptococci has increased. However, no vaccines containing these antigens have reached clinical trials. Three strategies have been used to develop conserved antigen vaccine candidates: use of the conserved region of the M protein; use of well described virulence factors as antigens, including streptococcal C5a peptidase, streptococcal carbohydrate, fibronectin-binding proteins, cysteine protease and streptococcal pili; and use of reverse vaccinology to identify novel antigens.

Summary: Several vaccine candidates against GAS infection are in varying stages of preclinical and clinical development. Although there is great hope that one of these vaccine candidates will reach licensure in the next decade, only one, the multivalent N-terminal vaccine, has entered clinical trials in the last 30 years. Although strong advocacy for GAS vaccine development is important, there remains an urgent need to institute available public health control measures against GAS diseases globally, particularly in developing countries.

Keywords Group A streptococcal
GAS
vaccine
DOI http://dx.doi.org/10.1097/QCO.0b013e328332bbfe   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 47 Abstract Views  -  Detailed Statistics
Created: Fri, 26 Mar 2010, 14:12:55 CST